US2004247562A1PendingUtilityA1
Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3
Priority: Sep 28, 2001Filed: Jan 18, 2002Published: Dec 9, 2004
Est. expirySep 28, 2021(expired)· nominal 20-yr term from priority
C07K 16/243C12N 15/11C12Q 2600/156C12Q 1/6886
54
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker.
Claims
exact text as granted — not AI-modified1 . A mutated G-CSF mRNA or cDNA fragment having a deletion of an exon 3 region for use as a diagnostic cancer marker.
2 . A mutated G-CSF protein having a deletion of an amino acid sequence corresponding to an exon 3 region for use as a diagnostic cancer marker.
3 . A microarray for diagnosis of cancer comprising (a) a DNA fragment corresponding to exon 3 of a G-CSF gene, and (b) at least one of DNA fragments corresponding to exons 1, 2, 4 and 5 of said G-CSF gene are bound.
4 . A diagnostic agent for cancer comprising an antibody against a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to an exon 3 region of said G-CSF protein.
5 . A diagnostic kit for cancer comprising an antibody against a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to an exon 3 region of said G-CSF protein.
6 . A microarray for diagnosis of cancer comprising an antibody against a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to an exon 3 region of said G-CSF protein.
7 . (Cancelled)
8 . A primer for use in amplification of a G-CSF gene in a G-CSF nucleic acid sample obtained from mammalian tissues or cells, wherein said primer is selected from the group consisting of the following nucleotide sequence pairs:
sense:
5′-ACCCCCCTGGGCCCTGCC-3′
(SEQ ID NO. 1)
and
antisense:
5′-TCAGGGCTGGGCAAGGTG-3′;
(SEQ ID NO. 2)
sense:
5′-ACCCCCCTGGGCCCTGCC-3′
(SEQ ID NO. 1)
and
antisense:
5′-CAGCTGCAGGGCCTGGCT-3′;
(SEQ ID NO. 5)
sense:
5′-ACCCCCCTGGGCCCTGCC-3′
(SEQ ID NO. 1)
and
antisense:
5′-CGCTATGGAGTTGGCTCAAGC-3′;
(SEQ ID NO. 6)
sense:
5′-ACCCCCCTGGGCCCTGCC-3′
(SEQ ID NO. 1)
and
antisense:
5′-CAGCTTCTCCTGGAGCGC-3′;
(SEQ ID NO. 9)
sense:
5′-ATCCAGGGCGATGGCGCAGCG-3′
(SEQ ID NO. 3)
and
antisense:
5′-TCAGGGCTGGGCAAGGTG-3′;
(SEQ ID NO. 2)
sense:
5′-ATCCAGGGCGATGGCGCAGCG-3′
(SEQ ID NO. 3)
and
antisense:
5′-CAGCTGCAGGGCCTGGCT-3′;
(SEQ ID NO. 5)
sense:
5′-ATCCAGGGCGATGGCGCAGCG-3′
(SEQ ID NO. 3)
and
antisense:
5′-CGCTATGGAGTTGGCTCAAGC-3′;
(SEQ ID NO. 6)
sense:
5′-TGTGCCACCTACAAGCTGTGC-3′
(SEQ ID NO. 4)
and
antisense:
5′-TCAGGGCTGGGCAAGGTG-3′;
(SEQ ID NO. 2)
sense:
5′-TGTGCCACCTACAAGCTGTGC-3′
(SEQ ID NO. 4)
and
antisense:
5′-CAGCTGCAGGGCCTGGCT-3′;
(SEQ ID NO. 5)
and
sense:
5′-TGTGCCACCTACAAGCTGTGC-3′
(SEQ ID NO. 4)
and
antisense:
5′-CGCTATGGAGTTGGCTCAAGC-3′.
(SEQ ID NO. 6)
9 . A mutated G-CSF protein having a deletion of an amino acid sequence corresponding to an exon 3 region.
10 . An antibody specifically binding to the mutated G-CSF protein of claim 9 .
11 . The antibody as set forth in claim 10 , wherein the antibody is a polyclonal antibody.
12 . The antibody as set forth in claim 10 , wherein the antibody is a monoclonal antibody.Join the waitlist — get patent alerts
Track US2004247562A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.